克拉生坦逆转动脉瘤性蛛网膜下腔出血后血管痉挛的初步研究
REVERSE 为前瞻性、多中心、开放标签、两阶段初步研究,纳入动脉瘤性蛛网膜下腔出血后发生中重度血管造影血管痉挛的成人患者,静脉给予克拉生坦 15 mg/小时。主要终点(3 小时全局大血管痉挛逆转)在 11 例可评估患者中仅 3 例(27.3%;95%CI 6.0-61.0)达到,因预设中期分析标准停止招募。探索性分析显示 24 小时多数患者远端血管床痉挛改善。
要点
- 克拉生坦 15 mg/小时对已形成的大血管痉挛 3 小时逆转率低(27.3%)。
- 24 小时探索性分析显示远端血管床扩张效应明显,多数患者改善。
- 研究因中期分析提前终止,结果支持在 REACT 试验中纳入已痉挛患者。
核心结论
- 克拉生坦对已形成的大血管痉挛 3 小时逆转率有限,但 24 小时探索性分析提示对远端血管床有明确扩张效应。
研究设计与样本
- 前瞻性、多中心、开放标签、两阶段初步研究,纳入动脉瘤性蛛网膜下腔出血后发生中重度血管造影血管痉挛的成人患者,静脉给予克拉生坦 15 mg/小时。
主要发现
- 主要终点(3 小时全局大血管痉挛逆转)在 11 例可评估患者中 3 例达到(27.3%;95%CI 6.0-61.0)。
- 探索性分析中,3 小时和 24 小时分别有 50.0% 和 77.8% 的患者在≥2 个远端节段显示痉挛显著逆转或改善至入院状态。
- 探索性分析中,3 小时和 24 小时分别有 28.6% 和 77.8% 的患者在≥2 个近端节段显示痉挛显著逆转或改善至入院状态。
临床怎么用
- 克拉生坦对已形成的大血管痉挛 3 小时逆转效果有限,但 24 小时可能改善远端血管床痉挛。
局限性
- 研究因预设中期分析标准在第一阶段后停止招募,样本量小(11 例可评估)。
- 开放标签设计,探索性分析结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clazosentan, an endothelin-1 receptor antagonist, has been shown to prevent the development of large vessel angiographic vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). It has been hypothesized that clazosentan can also reverse established angiographic vasospasm. METHODS: The REVERSE (resynchronization reverses remodeling in systolic left ventricular dysfunction) study was a prospective, multicenter, open-label, 2-stage pilot study of adult patients with aSAH who had received intravenous clazosentan (15 mg/hour) after developing moderate-to-severe angiographic vasospasm. The primary efficacy endpoint was the reversal of global cerebral vasospasm in large cerebral artery segments 3 hours after clazosentan initiation. The secondary endpoints included large artery vasospasm reversal at 24 hours and the maximum change in the angiographic cerebral circulation time. The change in vasospasm severity in the proximal and distal segments was investigated in an exploratory analysis. RESULTS: The primary efficacy endpoint was met in 3 of 11 evaluable patients (27.3%; 95% confidence interval, 6.0-61.0). However, recruitment was stopped after stage 1 in accordance with the predefined interim analysis criteria. In the exploratory analysis, 50.0% and 77.8% of the patients showed a significant reversal of vasospasm or improvement to the admission state in ≥2 distal segments at 3 and 24 hours and 28.6% and 77.8% in ≥2 proximal segments, respectively. CONCLUSIONS: Although the main analysis showed a reversal of large vessel vasospasm 3 hours after clazosentan initiation in a few patients, the exploratory analysis indicated a clear pharmacodynamic dilating effect on vasospastic cerebral vessels at 24 hours in most patients, in particular, in the distal arterial beds. This observation supported the inclusion of patients with established vasospasm in the ongoing REACT (prevention and treatment of vasospasm with clazosentan) trial.
引用
- Higashida RT, Bruder N, Gupta R, et al. Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study. World Neurosurg. 2019. PMID: 31054336. doi:10.1016/j.wneu.2019.04.222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。